We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

68 hedge funds and large institutions have $372M invested in Lyell Immunopharma in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

125% more capital invested

Capital invested by funds: $165M → $372M (+$207M)

15% more funds holding

Funds holding: 59 → 68 (+9)

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

3.33% more ownership

Funds ownership: 53.62% → 56.95% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

97% less call options, than puts

Call options by funds: $34K | Put options by funds: $1.15M

Holders
68
Holders Change
+9
Holders Change %
+15.25%
% of All Funds
0.83%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
15
Increased
18
Reduced
16
Closed
4
Calls
$34K
Puts
$1.15M
Net Calls
-$1.11M
Net Calls Change
-$754K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.02M
2
Invesco
Invesco
Georgia
+$2.21M
3
Goldman Sachs
Goldman Sachs
New York
+$2.16M
4
DC
Decheng Capital
California
+$2.16M
5
Marshall Wace
Marshall Wace
United Kingdom
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
VP
venBio Partners
California
-$3.04M
2
Millennium Management
Millennium Management
New York
-$1.49M
3
O
OrbiMed
New York
-$840K
4
Renaissance Technologies
Renaissance Technologies
New York
-$548K
5
RC
RBF Capital
California
-$471K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.32M +$133K +5,929 +16%
IC
27
Ikarian Capital
Texas
$1.26M -$60.8K -2,718 -6%
Renaissance Technologies
28
Renaissance Technologies
New York
$1.22M -$548K -24,500 -38%
Canada Pension Plan Investment Board
29
Canada Pension Plan Investment Board
Ontario, Canada
$988K +$60.4K +2,700 +9%
Northern Trust
30
Northern Trust
Illinois
$932K +$48.2K +2,152 +8%
SPS
31
Susquehanna Portfolio Strategies
Pennsylvania
$640K – – –
CGL
32
Clarius Group LLC
Washington
$614K – – –
BCM
33
Bridgeway Capital Management
Texas
$554K – – –
Barclays
34
Barclays
United Kingdom
$491K +$331K +14,775 +1,240%
Two Sigma Investments
35
Two Sigma Investments
New York
$481K -$117K -5,211 -25%
UBS Group
36
UBS Group
Switzerland
$406K -$180K -8,039 -38%
T. Rowe Price Associates
37
T. Rowe Price Associates
Maryland
$405K – – –
Jane Street
38
Jane Street
New York
$382K +$278K +12,409 New
Point72 Asset Management
39
Point72 Asset Management
Connecticut
$353K +$257K +11,480 New
BFM
40
Boothbay Fund Management
New York
$293K -$60.8K -2,718 -22%
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$279K +$203K +9,051 New
ECM
42
ExodusPoint Capital Management
New York
$262K +$190K +8,511 New
Bank of America
43
Bank of America
North Carolina
$248K +$75.3K +3,366 +72%
Raymond James Financial
44
Raymond James Financial
Florida
$243K +$177K +7,900 New
CS
45
Candriam SCA
Luxembourg
$234K +$170K +7,617 New
BP
46
BBR Partners
New York
$210K +$153K +6,834 New
Citigroup
47
Citigroup
New York
$130K +$71.7K +3,203 +311%
CUAMC
48
China Universal Asset Management Company
China
$106K +$2.01K +90 +3%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$97.6K +$63K +2,815 +793%
Fidelity Investments
50
Fidelity Investments
Massachusetts
$56.3K -$20K -893 -33%
1
2
3

LYEL Hedge Fund Activity: Q4 2025 in Review

68 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2025, worth a combined $372M — up 125% from $165M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LYEL positions and 4 closed out — a net gain of 11 holders — while 18 added to existing stakes and 16 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $3.02M. The largest seller was venBio Partners, cutting an estimated $3.04M.

  • 68 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2025, up from 59 in Q3 2025.
  • Funds reported $372M of Lyell Immunopharma stock for Q4 2025, up 125% quarter-over-quarter.
  • 15 funds opened new Lyell Immunopharma positions in Q4 2025 and 4 closed out, a net change of +11 holders.
  • The largest Lyell Immunopharma buyer in Q4 2025 was Susquehanna International Group, an estimated $3.02M added.
  • The largest Lyell Immunopharma seller in Q4 2025 was venBio Partners, an estimated $3.04M sold.

Based on aggregated 13F filings for Q4 2025.